CELLAVISION AB The information was submitted to the public on January 29, 2018 at 8:20 CET
CellaVision will publish the year-end bulletin for 2017 on February 9, 2018 at 08:20 CET. The report will be available at www.cellavision.com
In connection with the release of the year-end bulletin analysts, investors and media are hereby invited to a telephone conference and audio webcast at 11:00 CET where Zlatko Rihter, CEO, will present and comment the report.
The presentation will be in English via a conference call or audio webcast:
https://tv.streamfabriken.com/cellavision-q4-2017
Phone number for the conference:
SE: +46856642669
UK: +442030089809
US: +18557532236
No pre-registration is required. Please dial in 5-10 minutes prior to the scheduled start time in order to facilitate a timely start.
About CellaVision
CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products replaces manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the market support organizations in the US, Canada, China, Sweden, Japan, UAE, Korea, Australia, France, Germany, Brazil and Great Britain. In 2016 sales were SEK 265 million and the company's growth target is 15 % per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CellaVision AB via Globenewswire
